-
-
-
-
-
-
-
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
-
-
-
-
-
-
-
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
-
-
-
-
-
-
-
Biotech stocks: Q3 earnings preview
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
-
-
-
-
-
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 64c ; Offers Guidance
-
-
-
-
-
-
-
Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance
-
-
-
-
-
-
-
2Q24 U.S. biotech earnings preview
-
1,223,694 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

